Ovid Therapeutics Inc [OVID] stock is trading at $0.95, up 8.58%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OVID shares have gain 26.25% over the last week, with a monthly amount drifted -69.39%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ovid Therapeutics Inc [NASDAQ: OVID] stock has seen the most recent analyst activity on June 18, 2024, when Oppenheimer downgraded its rating to a Perform. Previously, B. Riley Securities started tracking the stock with Buy rating on April 30, 2024, and set its price target to $9. On April 29, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $9 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $8 on April 05, 2024. BTIG Research initiated its recommendation with a Buy and recommended $11 as its price target on December 21, 2023. Oppenheimer started tracking with a Outperform rating for this stock on October 13, 2023, and assigned it a price target of $8. In a note dated April 20, 2021, Cantor Fitzgerald downgraded an Neutral rating on this stock but restated the target price of $4.
Ovid Therapeutics Inc [OVID] stock has fluctuated between $0.68 and $4.14 over the past year. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $0.95 at the most recent close of the market. An investor can expect a potential return of 671.58% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Ovid Therapeutics Inc [NASDAQ:OVID] reported sales of 0.47M for the trailing twelve months, which represents a growth of 123.70%. Gross Profit Margin for this corporation currently stands at 387.99% with Operating Profit Margin at -130.52%, Pretax Profit Margin comes in at -107.02%, and Net Profit Margin reading is -107.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.54 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8860 points at the first support level, and at 0.8230 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9960, and for the 2nd resistance point, it is at 1.0430.
Ratios To Look Out For
For context, Ovid Therapeutics Inc’s Current Ratio is 10.47. Further, the Quick Ratio stands at 10.47, while the Cash Ratio is 3.46. Considering the valuation of this stock, the price to sales ratio is 143.24, the price to book ratio is 0.86.
Transactions by insiders
Recent insider trading involved LEVIN JEREMY M, CEO, that happened on Mar 18 ’24 when 18248.0 shares were purchased.
